Table 1.
Characteristics of hormone receptor-positive patients, eligible and non-eligible for RS assessment
| Characteristics, n (%) | PACS-01 (n = 1610) | Eligible (n = 530) | Non-eligible (n = 1080) | p |
|---|---|---|---|---|
| FEC-D | 820 (50.9) | 268 (50.6) | 552 (51.1) | 0.84 |
| Age ≥ 50 years | 809 (50.2) | 250 (47.2) | 559 (51.8) | 0.08 |
| Mastectomy | 708 (44.0) | 215 (40.6) | 493 (45.6) | 0.053 |
| ≥ 4 positive nodes | 595 (37.0) | 210 (39.6) | 385 (35.6) | 0.12 |
| Tumor size > 20 mm | 701 (47.7) | 244 (49.3) | 457 (46.9) | 0.28 |
| Missing | 141 | 35 | 106 | |
| Ductal carcinoma | 1204 (74.8) | 381 (71.9) | 823 (76.2) | 0.06 |
| SBR grade | 0.31 | |||
| Grade 1 | 216 (14.4) | 76 (15.3) | 140 (14.0) | |
| Grade 2 | 788 (52.5) | 251 (50.4) | 537 (53.6) | |
| Grade 3 | 496 (33.1) | 171 (34.3) | 325 (32.4) | |
| Missing | 110 | 32 | 78 | |
| Ki-67 expression ≥14% [19] | 270 (36.7) | 198 (40.5) | 72 (29.1) | 0.003 |
| Missing | 874 | 41 | 833 | |
| HER2-positive | 81 (9.7) | 46 (8.8) | 35 (11.3) | 0.23 |
| Missing | 776 | 5 | 771 | |
| Hormone receptor by IHC | ||||
| ER+ | 1493 (92.7) | 506 (95.5) | 987 (91.4) | 0.003 |
| PgR+ | 1186 (73.7) | 355 (67.0) | 831 (76.9) | < 0.001 |
| ER+/PgR+ | 1069 (66.4) | 331 (62.5) | 738 (68.3) | < 0.001 |
| ER+/PgR- | 424 (26.3) | 175 (33.0) | 249 (23.1) | |
| ER-/PgR+ | 117 (7.3) | 24 (4.5) | 93 (8.6) | |
DFS disease-free survival, FEC-D 3 cycles of FEC (6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 3 cycles of docetaxel 100 mg/m2, FEC100 6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, SBR Scarff–Bloom Richardson, IHC immunohistochemistry, ER estrogen receptor, PgR progesterone receptor